© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
October 28, 2020
The authors noted that research is still needed to establish standards for cell mobilization and immune-conditioning regimens.
Patients treated surgically reported better outcomes, including reduced AED use, higher rates of survival, and fewer epilepsy-related ED visits, hospitalizations, and outpatient visits.
The Medical Director of The Neuroscience Institute at UW Medicine Valley Medical Center discussed the landscape of therapy for tonic-clonic seizures and how lacosamide might fit into the paradigm.
The professor of neurology at the NYU Langone Grossman School of Medicine discussed a recent study she and colleagues conducted on new neurological disorders in patients with COVID-19.
October 27, 2020
The FDA told Xeris that it could advance diazepam directly into a phase 3 registration study for both pediatric and adult patients with epilepsy after reviewing phase 1b results.
The educational webinar series will feature 7 of the world leaders in Dravet Syndrome and will conclude on November 16 with a presentation from Ian Miller, MD.
David Dodick, MD, and Robert Cowan, MD, FAAN, review changes to the treatment landscape for acute migraine.
Kristina Simonyan, MD, PhD, DrMed, and Davide Valeriani, PhD, discussed the translational potential of DystoniaNet, and its potential to be adjusted for use in additional disease states.
The section chief of pediatric neurology at Nationwide Children’s Hospital discusses some of the challenges that patients with Lennox-Gastaut syndrome and their caregivers face.